Molbio Diagnostics IPO GMP History
Molbio Diagnostics IPO has been listed on August 17, 2026 at a listing price of ₹980, against the issue price of ₹807 — a gain of ₹173 (+21.44%). The GMP peaked at ₹220 on 6 August 2026 and reached a low of ₹115 on 14 August 2026. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Molbio Diagnostics IPO raised ₹939.7 Cr. through its IPO at a price band of ₹768 to ₹807 per share, with a lot size of 18 shares. The IPO was open for subscription from 10 Aug 2026 to 12 Aug 2026.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 8 Sep, 1:37 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 17 Aug 2026 | ₹ 120 | — | 14.87% | — | — |
| 16 Aug 2026 | ₹ 120 | ▼ | 14.87% | — | — |
| 15 Aug 2026 | ₹ 125 | ▲ | 15.49% | — | — |
| 14 Aug 2026 | ₹ 115 | ▼ | 14.25% | — | — |
| 13 Aug 2026 | ₹ 156 | ▲ | 19.33% | — | — |
| 12 Aug 2026 | ₹ 154 | ▲ | 19.08% | — | — |
| 11 Aug 2026 | ₹ 138 | ▲ | 17.10% | — | — |
| 10 Aug 2026 | ₹ 127 | ▼ | 15.74% | — | — |
| 09 Aug 2026 | ₹ 132 | ▲ | 16.36% | — | — |
| 08 Aug 2026 | ₹ 130 | ▼ | 16.11% | — | — |
| 07 Aug 2026 | ₹ 180 | ▼ | 22.30% | — | — |
| 06 Aug 2026 | ₹ 220 | ▲ | 27.26% | — | — |
| 05 Aug 2026 | ₹ 120 | — | 14.87% | — | — |
Molbio Diagnostics IPO dates
Key dates from opening to listing. Today is 6 November.
- Open 10 Aug 2026
- Close 12 Aug 2026
- Allotment 13 Aug 2026
- Refund/credit 14 Aug 2026
- Listing 17 Aug 2026
Molbio Diagnostics IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹807 |
|---|---|
| GMP-based estimate (pre-listing) | ₹927 (+14.9%) |
| Listing gain / loss | +₹173 per share |
| Listing date | 17 Aug, 2026 |
| Actual listing price | ₹980 (+21.44%) |
Is Molbio Diagnostics IPO GMP reliable?
Grey market premium for Molbio Diagnostics IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Molbio Diagnostics IPO full review for a fundamentals-based assessment before making any grey market trades.
Molbio Diagnostics IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Molbio Diagnostics IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Molbio Diagnostics IPO
Molbio Diagnostics Limited was started in October 2000. It is a global point-of-care molecular diagnostics company. It does research, development, manufacturing and selling of quick diagnostic solutions for infectious diseases as well as non-communicable diseases.
Its main product is the Truenat platform. This is a portable, battery-operated PCR based molecular testing system. It is made for places where lab facilities are limited, and it gives accurate results within an hour.
The company offers testing for more than 30 diseases through 43 diagnostic tests. These include tuberculosis, COVID-19, HIV, Hepatitis B and C, and HPV. Through its subsidiaries and tie-ups, it also provides radiology, digital pathology and breast health screening solutions. It keeps adding new products through its own R&D.
The company runs six manufacturing plants in India and serves customers in over 90 countries. Its customers include government health programmes, diagnostic labs, hospitals and international healthcare bodies.
It holds a good number of patents and global certifications, and has grown through some strategic acquisitions. As on 31 March 2026, the company had 1,225 permanent employees across R&D, manufacturing, quality, sales, finance and corporate functions.
Frequently asked
What is the GMP of Molbio Diagnostics IPO?
The current Grey Market Premium (GMP) of Molbio Diagnostics IPO is ₹ 120.
What is the Kostak Price of Molbio Diagnostics IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Molbio Diagnostics IPO is not available.
What is the Subject to Sauda Price of Molbio Diagnostics IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Molbio Diagnostics IPO?
Molbio Diagnostics IPO listed on August 17, 2026 at ₹980, against the issue price of ₹807 — a gain of +21.44%.
How did the GMP of Molbio Diagnostics IPO trend before listing?
The GMP of Molbio Diagnostics IPO was stable in its final days before listing. The GMP peaked at ₹220 on 6 August 2026. View the day-wise table above for the complete GMP history.
Explore Molbio Diagnostics IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
